keyword
MENU ▼
Read by QxMD icon Read
search

Breast chemotherapy adjuvant and primary

keyword
https://www.readbyqxmd.com/read/28428927/limitations-of-personalized-medicine-and-gene-assays-for-breast-cancer
#1
David Tiberi, Laura Masucci, Daniel Shedid, Isabelle Roy, Toni Vu, Erica Patocskai, André Robidoux, Philip Wong
Adjuvant systemic treatments reduce the risk of breast cancer recurrence following the local treatment of primary stage I-III breast cancers. For patients with hormone-positive breast cancers receiving hormonal therapy, the risk of distant recurrence is under 20% and therefore, many patients may potentially be spared of chemotherapy. Consequently, several molecular signatures based on gene expression were developed to better determine which breast cancer patients would benefit from chemotherapy. We present the case of a 62-year-old woman diagnosed with an early stage hormone receptor-positive breast cancer that was treated with a partial mastectomy...
March 17, 2017: Curēus
https://www.readbyqxmd.com/read/28424560/an-exploratory-study-of-host-polymorphisms-in-genes-that-clinically-characterize-breast-cancer-tumors-and-pretreatment-cognitive-performance-in-breast-cancer-survivors
#2
Theresa A Koleck, Catherine M Bender, Beth Z Clark, Christopher M Ryan, Puja Ghotkar, Adam Brufsky, Priscilla F McAuliffe, Priya Rastogi, Susan M Sereika, Yvette P Conley
PURPOSE: Inspired by the hypothesis that heterogeneity in the biology of breast cancers at the cellular level may account for cognitive dysfunction symptom variability in survivors, the current study explored relationships between host single-nucleotide polymorphisms (SNPs) in 25 breast cancer-related candidate genes (AURKA, BAG1, BCL2, BIRC5, CCNB1, CD68, CENPA, CMC2, CTSL2, DIAPH3, ERBB2, ESR1, GRB7, GSTM1, MELK, MKI67, MMP11, MYBL2, NDC80, ORC6, PGR, RACGAP1, RFC4, RRM2, and SCUBE2), identified from clinically relevant prognostic multigene-expression profiles for breast cancer, and pretreatment cognitive performance...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28420722/low-tumor-mitochondrial-dna-content-is-associated-with-better-outcome-in-breast-cancer-patients-receiving-anthracycline-based-chemotherapy
#3
Marjolein J A Weerts, Antoinette Hollestelle, Anieta M Sieuwerts, John A Foekens, Stefan Sleijfer, John W M Martens
In this study, we aimed to explore whether low levels of mitochondrial DNA (mtDNA) content in the primary tumor could predict better outcome for breast cancer patients receiving anthracycline-based therapies. We hypothesized that tumor cells with low mtDNA content are more susceptible to mitochondrial damage induced by anthracyclines, and thus are more susceptible to anthracycline treatment.<br /><br />Experimental Design: We measured mtDNA content by a quantitative PCR approach in 295 primary breast tumor specimens originating from two well-defined cohorts: 174 lymph node-positive patients who received adjuvant chemotherapy and 121 patients with advanced disease who received chemotherapy as first-line palliative treatment...
April 18, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28401821/-70-gene-signature-as-an-aid-to-treatment-decisions-in-early-stage-breast-cancer
#4
J J M van der Hoeven
OBJECTIVE: The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical outcome in women with early-stage breast cancer. We sought to provide prospective evidence of the clinical utility of the addition of the 70-gene signature to standard clinical-pathological criteria in selecting patients for adjuvant chemotherapy. METHODS: In this randomized, phase 3 study, we enrolled 6693 women with early-stage breast cancer and determined their genomic risk (using the 70-gene signature) and their clinical risk (using a modified version of Adjuvant! Online)...
2017: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/28397346/magnetic-resonance-imaging-patterns-of-tumor-regression-in-breast-cancer-patients-after-neo-adjuvant-chemotherapy-and-an-analysis-of-the-influencing-factors
#5
ManMan Li, Bin Xu, Yingbo Shao, Hui Liu, BingJie Du, JunHui Yuan
The objective of this study was to analyze the patterns of breast tumor shrinkage in patients after neo-adjuvant chemotherapy (NAC) based on magnetic resonance imaging (MRI), and to evaluate the influential factors. Preoperative breast dynamic contrast-enhanced MRI was performed on 88 patients before NAC, every 2 weeks during their chemotherapy treatment, and the week before their surgery. The MRI enhancement pattern of the primary tumors was classified into one of four categories based on BI-RADS-MRI: type I (postcontrast mass image), II (multiple small masses image), III (postcontrast mass image with peripheral non-mass enhancement image), and IV (nonmass enhancement image)...
April 10, 2017: Breast Journal
https://www.readbyqxmd.com/read/28395915/local-failure-and-acute-radiodermatological-toxicity-in-patients-undergoing-radiation-therapy-with-and-without-post-mastectomy-chest-wall-bolus-is-bolus-ever-necessary
#6
Stephen Abel, Paul Renz, Mark Trombetta, Michael Cowher, E Day Werts, Thomas B Julian, Rodney Wegner
PURPOSE: Postmastectomy chest wall radiation therapy has historically used bolus to increase dose at the skin surface. Despite the theoretical benefits of bolus, the clinical implications of locoregional tumor control, cosmesis, and the incidence of radiodermatitis are less well characterized. We hypothesized that treatment in the presence or absence of bolus results in equivalent chest wall recurrence rates, but its presence results in more severe acute dermatologic toxicity. METHODS AND MATERIALS: Locally advanced breast cancer patients undergoing chest wall radiation therapy were retrospectively reviewed from 2005 to 2015 (n = 106; 53 with bolus, 53 without)...
October 30, 2016: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28386772/predictors-of-the-course-of-quality-of-life-during-therapy-in-women-with-primary-breast-cancer
#7
Achim Wöckel, L Schwentner, M Krockenberger, R Kreienberg, W Janni, M Wischnewsky, Kühn Thorsten, Flock Felix, Felberbaum Riccardo, M Blettner, S Singer
PURPOSE: Multimodal therapies affect the quality of life (QoL) of patients with primary breast cancer (PBC). The objectives of this prospective study were to explore the changes in QoL from diagnosis to conclusion of adjuvant therapy and to identify predictive factors of QoL. METHODS: Before surgery (t1), before onset of adjuvant treatment (t2) and after completion of adjuvant chemo- or radiotherapy (t3), patients with PBC (n = 759) completed the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire, Charlson Comorbidity Index, Patient Health Questionnaire and Perceived Involvement in Care Scales...
April 6, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28383379/effect-of-a-ph-balanced-vaginal-gel-on-dyspareunia-and-sexual-function-in-breast-cancer-survivors-who-were-premenopausal-at-diagnosis-a-randomized-controlled-trial
#8
Yun Hwan Kim, Sanghui Park, Maria Lee, Seokyung Hahn, Myung Jae Jeon
OBJECTIVE: To assess whether a pH-balanced vaginal gel containing lactic acid is more effective than a placebo (lactate-free gel) in improving dyspareunia and sexual function among breast cancer survivors who were premenopausal at diagnosis and had dyspareunia after adjuvant chemotherapy. METHODS: In a single-center, double-blind, randomized trial, a pH-balanced gel or placebo was administered three times per week at bedtime as well as during sexual intercourse for 8 weeks...
May 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28379421/impact-of-baseline-bmi-and-weight-change-in-cctg-adjuvant-breast-cancer-trials
#9
R Yerushalmi, B Dong, J W Chapman, P E Goss, M N Pollak, M J Burnell, M N Levine, V H C Bramwell, K I Pritchard, T J Whelan, J N Ingle, L E Shepherd, W R Parulekar, L Han, K Ding, K A Gelmon
Background: We hypothesized that increased baseline BMI and BMI change would negatively impact clinical outcomes with adjuvant breast cancer systemic therapy. Methods: Data from chemotherapy trials MA.5 and MA.21; endocrine therapy MA.12, MA.14 and MA.27; and trastuzumab HERA/MA.24 were analyzed. The primary objective was to examine the effect of BMI change on breast cancer-free interval (BCFI) landmarked at 5-years; secondary objectives included BMI changes at 1- and 3-years; BMI changes on disease-specific survival (DSS) and overall survival (OS); and effects of baseline BMI...
March 31, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28376188/regional-nodal-irradiation-after-breast-conserving-surgery-for-early-her2-positive-breast-cancer-results-of-a-subanalysis-from-the-altto-trial
#10
Isabelle Gingras, Eileen Holmes, Evandro De Azambuja, David H A Nguyen, Miguel Izquierdo, Jo Anne Zujewski, Moshe Inbar, Bjorn Naume, Gianluca Tomasello, Julie R Gralow, Antonio C Wolff, Lyndsay Harris, Michael Gnant, Alvaro Moreno-Aspitia, Martine J Piccart, Hatem A Azim
Background: Two randomized trials recently demonstrated that regional nodal irradiation (RNI) could reduce the risk of recurrence in early breast cancer; however, these trials were conducted in the pretrastuzumab era. Whether these results are applicable to human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients treated with anti-HER2-targeted therapy is unknown. Methods: This retrospective analysis was performed on patients with node-positive breast cancer who were enrolled in the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization phase III adjuvant trial and subjected to BCS...
August 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28373466/a-retrospective-analysis-of-ki-67-index-and-its-prognostic-significance-in-over-800-primary-breast-cancer-cases
#11
Fabinshy Thangarajah, Insa Enninga, Wolfram Malter, Stefanie Hamacher, Birgid Markiefka, Lisa Richters, Stefan Krämer, Peter Mallmann, Verena Kirn
BACKGROUND/AIM: The Ki-67 index is chiefly important for distinguishing between luminal A and luminal B human epidermal growth factor receptor 2 (HER2neu)-negative breast cancer subtypes. However, its ability to predict response to chemotherapy is uncertain. PATIENTS AND METHODS: Patients treated for primary breast cancer at the University Hospital of Cologne were identified. Immunohistochemistry for Ki-67 detection was performed according to standard protocols...
April 2017: Anticancer Research
https://www.readbyqxmd.com/read/28364269/systemic-therapies-and-cognitive-impairment-for-breast-cancer-an-overview-of-the-current-literature
#12
REVIEW
Icro Meattini, Isacco Desideri, Giulio Francolini, Agnese Vannini, Marco Perna, Pietro Garlatti, Roberta Grassi, Lorenzo Livi
Both endocrine and chemotherapy can be utilized for breast cancer patients' management, in multiple setting (i.e., primary systemic therapy, adjuvant, metastatic treatment). Health-related quality of life in breast cancer survivors can be significantly influenced by cognitive impairment, which has been related in several previously reported experiences to systemic therapies administration. However, although the growing body of literature, the impact of both chemo- and endocrine therapy on cognitive function is currently unclear, due to many confounding factors (i...
May 2017: Medical Oncology
https://www.readbyqxmd.com/read/28341762/a-prospective-observational-study-on-effect-of-short-term-periodic-steroid-premedication-on-bone-metabolism-in-gastrointestinal-cancer-espresso-01
#13
Michio Nakamura, Atsushi Ishiguro, Tetsuhito Muranaka, Hiraku Fukushima, Satoshi Yuki, Kota Ono, Taichi Murai, Chika Matsuda, Ayane Oba, Kazufumi Itaya, Takayuki Sone, Masataka Yagisawa, Yuta Koike, Ayana Endo, Yoko Tsukuda, Yuji Ono, Takahiko Kudo, Atsushi Nagasaka, Shuji Nishikawa, Yoshito Komatsu
BACKGROUND: A multicenter prospective observational study evaluated the effect of gastrointestinal cancer chemotherapy with short-term periodic steroid premedication on bone metabolism. PATIENTS AND METHODS: Seventy-four patients undergoing chemotherapy for gastrointestinal cancer were studied. The primary endpoints were changes in bone mineral densities (BMDs) and metabolic bone turnover 16 weeks after initiation of chemotherapy. BMDs, measured by dual-energy x-ray absorptiometry, and serum cross-linked N-telopeptides of type I collagen (sNTX), and bone alkaline phosphatase (sBAP) were assessed for evaluation of bone resorption and formation, respectively...
March 24, 2017: Oncologist
https://www.readbyqxmd.com/read/28341761/cardiac-safety-of-dual-anti-her2-therapy-in-the-neoadjuvant-setting-for-treatment-of-her2-positive-breast-cancer
#14
Anthony F Yu, Jasmeet C Singh, Rui Wang, Jennifer E Liu, Anne Eaton, Kevin C Oeffinger, Richard M Steingart, Clifford A Hudis, Chau T Dang
BACKGROUND: Trastuzumab and pertuzumab are approved for the neoadjuvant treatment of human epidermal growth receptor 2 (HER2)-positive breast cancer, but cardiac safety data is limited. We report the cardiac safety of dose-dense doxorubicin and cyclophosphamide (AC) followed by paclitaxel, trastuzumab, and pertuzumab (THP) in the neoadjuvant setting followed by adjuvant trastuzumab-based therapy. METHODS: Fifty-seven patients treated with neoadjuvant dose-dense AC-THP followed by adjuvant trastuzumab-based therapy between September 1, 2013, and March 1, 2015, were identified...
March 24, 2017: Oncologist
https://www.readbyqxmd.com/read/28335887/trastuzumab-in-combination-with-weekly-paclitaxel-and-carboplatin-as-neo-adjuvant-treatment-for-her2-positive-breast-cancer-the-train-study
#15
Mette S van Ramshorst, Erik van Werkhoven, Ingrid A M Mandjes, Margaret Schot, Jelle Wesseling, Marie-Jeanne T F D Vrancken Peeters, Jetske M Meerum Terwogt, Monique E M Bos, Hendrika M Oosterkamp, Sjoerd Rodenhuis, Sabine C Linn, Gabe S Sonke
AIM: To determine the efficacy and safety of an anthracycline-free neo-adjuvant regimen consisting of weekly paclitaxel, carboplatin and trastuzumab in HER2-positive breast cancer. PATIENTS AND METHODS: Patients with stage II or III HER2-positive breast cancer received weekly paclitaxel ([P], 70 mg/m(2)), trastuzumab ([T], 2 mg/kg, loading dose 4 mg/kg) and carboplatin ([C], AUC = 3 mg ml(-1) min) for 24 weeks. In weeks 7, 8, 15, 16, 23 and 24, trastuzumab was administered without chemotherapy...
March 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28243896/breast-cancer-specific-survival-in-patients-with-lymph-node-positive-hormone-receptor-positive-invasive-breast-cancer-and-oncotype-dx-recurrence-score-results-in-the-seer-database
#16
Megan C Roberts, Dave P Miller, Steven Shak, Valentina I Petkov
PURPOSE: The Oncotype DX(®) Breast Recurrence Score™ (RS) assay is validated to predict breast cancer (BC) recurrence and adjuvant chemotherapy benefit in select patients with lymph node-positive (LN+), hormone receptor-positive (HR+), HER2-negative BC. We assessed 5-year BC-specific survival (BCSS) in LN+ patients with RS results in SEER databases. METHODS: In this population-based study, BC cases in SEER registries (diagnosed 2004-2013) were linked to RS results from assays performed by Genomic Health (2004-2014)...
February 27, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28228661/feasibility-of-an-exercise-intervention-for-fatigued-breast-cancer-patients-at-a-community-based-cardiac-rehabilitation-program
#17
Stefanie De Jesus, Lyndsay Fitzgeorge, Karen Unsworth, David Massel, Neville Suskin, Harry Prapavessis, Michael Sanatani
PURPOSE: Exercise is beneficial to quality of life after cancer treatment, yet few cancer survivors meet exercise guidelines. Our study sought to determine the feasibility of an oncology rehabilitation exercise program embedded within a cardiac rehabilitation program. METHODS: Patients who rated their fatigue >4/10 after completion of adjuvant chemotherapy for breast cancer were screened for eligibility and the outcomes were assessed (Piper Fatigue Scale, Functional Assessment of Cancer Therapy-Breast [FACT-B], Edmonton Symptom Assessment System, body composition, stress test, and physical activity measurement [accelerometer])...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28223032/-primary-breast-sarcomas-about-30%C3%A2-cases-treated-at-salah-azaiez-institute-in-tunisia
#18
O El Amine Elhadj, M Nasri, S Thabet, J Ben Hassouna, A Goucha, K Rahal, A Elmay, A Gamoudi
PURPOSE: To identify retrospectively prognostic factors of primary breast sarcoma and review its treatment modalities. MATERIALS AND METHODS: This is a descriptive study on 30 cases of primary breast sarcoma. We carried out a univariate and multivariate analysis correlating clinical, pathological and therapeutic parameters with disease-free survival and overall survival. RESULTS: The mean age was 46.8 years. The mean tumour size was 10cm...
February 17, 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/28217830/relationship-between-alcohol-metabolism-and-chemotherapy-induced-emetic-events-in-breast-cancer-patients
#19
Toshitaka Uomori, Yoshiya Horimoto, Kaoru Mogushi, Joe Matsuoka, Mitsue Saito
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) can negatively affect quality of life and treatment compliance in breast cancer patients. Habitual alcohol consumption reportedly shows an inverse correlation with CINV, though the underlying mechanism is unknown. Acetaldehyde dehydrogenase 2 (ALDH2), one of the two ALDH isozymes, is reportedly the major factor among several genetic polymorphisms possibly affecting alcohol metabolism. More than 40% of Japanese have ALDH2 mutations, while almost all Westerners have the wild type...
February 20, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28215665/11-years-follow-up-of-trastuzumab-after-adjuvant-chemotherapy-in-her2-positive-early-breast-cancer-final-analysis-of-the-herceptin-adjuvant-hera-trial
#20
David Cameron, Martine J Piccart-Gebhart, Richard D Gelber, Marion Procter, Aron Goldhirsch, Evandro de Azambuja, Gilberto Castro, Michael Untch, Ian Smith, Luca Gianni, Jose Baselga, Nedal Al-Sakaff, Sabine Lauer, Eleanor McFadden, Brian Leyland-Jones, Richard Bell, Mitch Dowsett, Christian Jackisch
BACKGROUND: Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early breast cancer, but long-term follow-up data are needed. We report the results of comparing observation with two durations of trastuzumab treatment at a median follow-up of 11 years, for patients enrolled in the HERA (HERceptin Adjuvant) trial. METHODS: HERA (BIG 1-01) is an international, multicentre, open-label, phase 3 randomised trial of 5102 women with HER2-positive early breast cancer, who were enrolled from hospitals in 39 countries between Dec 7, 2001, and June 20, 2005...
March 25, 2017: Lancet
keyword
keyword
43929
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"